EZH2 and melanoma: EZH2 and other PRC2 components are frequently amplified or overexpressed in melanoma, and several activating EZH2 mutations such as various mutations of tyrosine Y641 have been identified (Tiffen et al., 2016a; Hayward et al., 2017).